argenex SE $ARGX Stock Holdings Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans boosted its holdings in shares of argenex SE (NASDAQ:ARGX) by 1,953.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,823 shares of the company’s stock after purchasing an additional 10,296 shares during the period. Thrivent Financial for Lutherans’ holdings in argenex were worth $7,982,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. MAI Capital Management lifted its position in shares of argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares during the last quarter. Mather Group LLC. acquired a new position in shares of argenex in the 3rd quarter worth $50,000. TD Private Client Wealth LLC raised its position in shares of argenex by 750.0% during the third quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock worth $63,000 after purchasing an additional 75 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Rakuten Securities Inc. lifted its holdings in shares of argenex by 113.1% during the second quarter. Rakuten Securities Inc. now owns 130 shares of the company’s stock valued at $72,000 after purchasing an additional 69 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

argenex stock opened at $820.31 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The firm has a market cap of $50.76 billion, a PE ratio of 35.22, a P/E/G ratio of 0.73 and a beta of 0.37. The firm’s 50 day moving average price is $846.09 and its two-hundred day moving average price is $788.92.

Analyst Upgrades and Downgrades

ARGX has been the topic of a number of analyst reports. HC Wainwright lifted their price target on argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a report on Friday, December 19th. Robert W. Baird lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. Truist Financial lifted their price objective on shares of argenex from $950.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Evercore ISI boosted their target price on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, argenex currently has a consensus rating of “Moderate Buy” and an average price target of $986.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.